What Cefim (Cefixime) Treats: Main Uses and Benefits

Cefixime is an oral cephalosporin class of medication that may assist with managing infections caused by susceptible bacteria. It is applied across domains where additional symptomatic support is needed for acute bacterial infections affecting several key organ systems.

Cefixime is commonly used to help with symptoms related to inflammatory or irritative states in the urinary and respiratory systems. This includes supporting the management of conditions presenting with acute episodes such as uncomplicated urinary tract infections (UTIs), otitis media (middle ear infection), pharyngitis and tonsillitis (throat infections), acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea.

The drug supports the patient during difficult episodes by easing distress associated with these infections. When symptoms become temporarily overwhelming, Cefixime is a relevant option when short-term symptomatic assistance is needed.

“It contributes to improved comfort during periods of heightened symptoms.”

This class of medication is applied in addressing bacteria, and is generally not used to help with viral conditions like the common cold or flu.

---

Quick Fact: Supports Easing Symptoms that Create Noticeable Physiological Strain

Regulatory References

1. DailyMed Cefixime Drug Label

Eligibility Map: Who can and cannot use Cefim (Cefixime) — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and pediatric patients ge 6 months of age are the officially indicated populations [FDA/EMA]. Geriatric patients may use Cefixime, typically without dose adjustment based on age alone.
Populations for whom use is not recommended	The safety and efficacy have not been established for infants aged less than six months [FDA/EMA]. Some regulators advise that use is not recommended in children with renal insufficiency due to insufficient data.
Populations for whom use is contraindicated	Patients with a known hypersensitivity/allergy to Cefixime or any cephalosporin antibiotic [FDA/EMA]. Caution is required for patients with a history of penicillin allergy due to the potential for cross-allergenicity.
Condition-specific eligibility rules	Impaired Renal Function: Use is permitted, but dose adjustment is required for adults whose creatinine clearance is less than 60 mL/min. The chewable tablet form is a concern for patients with Phenylketonuria (PKU) as it contains phenylalanine.
Pregnancy and lactation eligibility status	Pregnant Women: Cefixime is classified as Pregnancy Category B and should be used only if clearly needed. Nursing Mothers: It is unknown if Cefixime is excreted in human milk; consideration should be given to discontinuing nursing temporarily.

Connection to the overall eligibility profile

Regulatory documents establish absolute non-eligibility through contraindications for patients with cephalosporin or severe penicillin allergies. Furthermore, they define non-established use for infants under six months of age. Use is made conditional by the need for dose adjustments in patients with renal impairment and by the caution required for use during pregnancy and lactation, strictly controlling the eligible patient population.

Interactions with other medicines and products

Interaction Type	Interacting Substance / Product	Regulatory Description of Outcome
Pharmacodynamic	Warfarin and Coumarin-type Anticoagulants	Co-administration may be associated with a fall in prothrombin activity, resulting in a documented increased prothrombin time (INR), with or without clinical bleeding. The risk of coagulation effects is also heightened in patients with renal impairment.
Exposure Modification	Carbamazepine	Elevated plasma concentrations of carbamazepine have been officially reported in postmarketing experience when Cefixime is administered concomitantly.
Interaction Restriction	Live Vaccines (e.g., BCG, Cholera, Typhoid)	A serious interaction is documented, as the antibiotic may compromise the intended therapeutic effect of the live bacterial vaccine strain.
Administration Kinetics	Food	The extent of absorption (AUC) is not significantly affected by food. However, the time to maximal absorption (Tmax) is formally documented to be slowed by approximately 0.8 hours.
Product Interference	Laboratory Tests	May cause false-positive results for urine glucose tests that use copper reduction methods (e.g., Benedict's solution) and for the Direct Coombs' test.

The official regulatory profile for Cefixime structures its interaction data around two primary components: pharmacodynamic interference with blood coagulation and pharmacokinetic alteration. The most notable interaction is the potential for increased prothrombin time when used with anticoagulants. The profile also addresses the reported increase in carbamazepine plasma levels, which warrants monitoring. Furthermore, documentation includes procedural constraints regarding co-administration with live bacterial vaccines and potential interferences with specific common laboratory diagnostic tests.

u1f52c How Cefim (Cefixime) Works

Cefim (Cefixime) exerts its effect through a defined enzyme-inhibition mechanism that leads to the active destruction of susceptible bacteria. Its action is focused on the bacterial cell structure.

---

Covalent Inhibition of Cell Wall Synthesis Enzymes

The core mechanism involves Cefixime acting as a covalent inhibitor of key bacterial enzymes known as Penicillin-binding proteins (PBPs), specifically the transpeptidases PBP 3, 1a, and 1b. By permanently binding to and inactivating these enzymes, the drug effectively blocks the final, critical cross-linking step in the assembly of the bacterial peptidoglycan cell wall.

---

The Cascade Leading to Bactericidal Lysis

The failure to construct a structurally rigid cell wall means the bacteria cannot withstand its high internal osmotic pressure. This structural failure initiates an irreversible cascade that causes the cell membrane to rupture, leading to bacterial cell lysis. This process results in the drug's bactericidal action.

---

Mechanistic Stability Against Bacterial Defense Enzymes

Cefixime's structure provides stability against many of the common bacterial defense enzymes (β-lactamases) that would typically degrade and neutralize older antibiotics. This mechanistic stability permits the drug's core action of PBP inhibition to remain effective against susceptible bacterial strains with certain enzymatic resistance mechanisms.

Official Administration Guidelines for Cefixime

Cefixime is administered exclusively via the oral route as tablets, capsules, chewable tablets, or an oral suspension. The official dosing and procedural instructions define the standard regimen based on patient population and physical condition.

---

Dosage and Frequency

• Adults: The recommended standard dose is 400 mg daily. This can be administered as a single 400 mg once-daily dose or divided into 200 mg every 12 hours. For infections caused by Streptococcus pyogenes, the therapeutic course must continue for a minimum of 10 days.
• Pediatric Patients (6 months or older): The dose is calculated at 8 mg/kg/day. This may be given as a single daily dose or divided into 4 mg/kg every 12 hours. The total daily dose must not exceed the 400 mg adult dose.

---

Administration Conditions and Adjustments

Feature	Official Labeled Instruction
Timing to Food	Tablets and capsules may be administered without regard to food.
Renal Impairment	Dose adjustment is required for kidney function impairment. For creatinine clearance 21-60 mL/min, the dose is typically reduced to 300 mg daily, and further reduced to 200 mg daily for clearance less than or equal to 20 mL/min.
Suspension/Chewables	The oral suspension must be reconstituted and shaken well before each dose. Chewable tablets must be chewed or crushed before swallowing; they should not be swallowed whole.
Missed Dose	If a dose is missed, it should be taken as soon as remembered. If it is almost time for the next dose, the missed dose should be skipped, and the regular schedule resumed. Double doses should be avoided.

---

These official instructions establish the precise framework for Cefixime use, specifying the oral route, standard frequency, and mandatory dose reductions based on age and renal function. This structured approach dictates how the medicine should be prepared and ingested.

Randomized Controlled Trials (RCTs) and systematic reviews constitute the research base that describes the observations made in defined patient groups. Research has been conducted to understand the research base related to various bacterial infections.

---

Evidence for Urinary Tract and Acute Respiratory Infections

Research has explored the use of Cefixime in clinical situations where symptoms may vary in intensity, such as uncomplicated urinary tract infections (UTIs). Studies in this area, predominantly involving non-pregnant adult women, were designed to measure clinical symptom resolution and microbiological clearance of the causative bacteria. The findings describe patterns observed in the short-term, such as how symptoms evolved in the observed populations during the study period. However, research highlights concerns related to emerging bacterial resistance patterns in certain common pathogens, which presents an ongoing area of study.

For pharyngitis (throat infections), tonsillitis, and acute exacerbations of chronic bronchitis (AECB), studies were conducted during periods of increased symptom activity. These trials monitored outcomes linked to inflammatory or irritative states and tracking laboratory measurements related to bacterial presence. These findings provide context but not individual predictions, and generally focus on the short-term symptom changes observed immediately following the defined time intervals of treatment.

---

Evidence for Uncomplicated Gonorrhea

Cefixime was evaluated in studies focusing on uncomplicated gonorrhea, a condition characterized by functional limitations and acute or disruptive episodes. Research scenarios involved comparative non-inferiority trials designed to measure microbiological clearance (eliminating the organism) and subsequent clinical outcomes. Findings indicate that Cefixime was observed in some studies to be associated with clearance, but research also highlights patterns indicating a possible decrease in bacterial susceptibility over time. Due to these findings, the certainty remains low, and this area represents an evolving uncertainty in the broader evidence landscape.

---

Evidence in Pediatric and Other Special Populations

Research has primarily focused on specific groups where the risk of certain infections is higher. Studies for acute otitis media (AOM), a condition where symptoms may vary in intensity, have largely been conducted in pediatric patients. The trials reported measurements of clinical success criteria in children, with some studies also including comparator groups. For other groups, such as pregnant patients studied for uncomplicated gonorrhea, or older adults, the data for certain groups remain insufficient, meaning the results apply mainly to the populations explicitly studied in the clinical trials.

---

Duration of Study Follow-up and Long-Term Data

The majority of clinical research studies for Cefixime focus on short-term symptom changes and outcomes related to physiological strain, particularly the microbiological clearance observed at the end of the treatment or shortly thereafter. While follow-up durations were included in these studies—sometimes extending up to four weeks—the long-term effects are not fully established or well characterized. There is limited information for outcomes related to the durability of the response or the frequency of infection recurrence over extended periods. Research provides context for short-term changes, but information related to outcomes assessed over extended durations remains limited.

---

Evidence Quality and Identified Research Gaps

The evidence quality varies across studies; the research covering the listed indications generally falls into the Moderate level. However, for certain conditions like uncomplicated gonorrhea, the evidence level Varies/Evolving due to external factors. The key limitations across the research include concerns over bacterial resistance that is still emerging and being studied. Furthermore, the available comparative evidence is limited for some indications, and for many conditions, the sample sizes were modest, meaning the findings describe group patterns, not personal outcomes. Research is ongoing, and the existing studies help show what has been observed so far, but do not determine whether an individual will respond similarly.

Key Studies & References

1. Label: CEFIXIME capsule - Official FDA Drug Label for Cefixime (DailyMed)
2. Cefixime - World Health Organization (WHO) Electronic Essential Medicines List (eEML)

Common questions about Cefim (Cefixime) (FAQ)

---

Q: Is Cefim considered a strong antibiotic?

A: Cefixime is classified as a third-generation cephalosporin antibiotic. According to official product information, its chemical structure provides stability against certain bacterial defense enzymes (beta-lactamases), which can typically neutralize older antibiotics. Its mechanism involves bactericidal action against susceptible bacteria, meaning it works to kill the bacterial cells.

---

Q: Does Cefim treat viral infections or only bacterial ones?

A: Cefixime is an antibacterial drug indicated only for infections caused by susceptible bacteria. Official regulatory documents state Cefixime is not effective against viral infections.

---

Q: Why do people sometimes get diarrhea when taking Cefim?

A: Diarrhea and loose stools are listed as common adverse reactions. In some cases, severe diarrhea may be linked to an overgrowth of Clostridioides difficile bacteria, known as CDAD, which is a serious adverse reaction noted in the safety information.

---

Q: What are the most common side effects of Cefim (Cefixime)?

A: The most frequent adverse reactions affect the digestive system, commonly including diarrhea, loose stools, abdominal pain, nausea, and vomiting. Other reactions like headache and dizziness have also been reported in the official prescribing information.

---

Q: Can Cefim cause a yeast infection?

A: Adverse reactions reported with Cefixime use include candidiasis, which is commonly known as a yeast infection. This is listed in the drug's safety information.

---

Q: Is it normal to feel a bit nauseous after taking Cefim?

A: Nausea is listed as a common adverse reaction associated with Cefixime, according to the official prescribing information.

---

Q: Can Cefim cause dizziness or affect driving?

A: Adverse reactions reported include dizziness and headache. Official labeling does not contain specific guidance on driving ability, but patients should be aware of how the medicine affects them before engaging in activities that require focus.

---

Q: Are there any dietary restrictions while taking Cefim?

A: The official product label states that Cefixime tablets and capsules may be administered without regard to food. Unless otherwise directed by a healthcare professional, a normal diet may be continued.

---

Q: Does Cefim affect blood sugar levels?

A: Official information indicates that Cefixime may cause a false-positive result for certain urine glucose tests that use copper reduction methods. This means the medication may interfere with these specific lab measurements, but the label does not specify an effect on the body's actual blood glucose levels.

---

Q: How is Cefim eliminated from the body?

A: The official product information indicates that Cefixime is eliminated from the body primarily by excretion in the urine, with a portion also excreted in the bile.

---

Q: What are the symptoms of Clostridium difficile infection related to Cefim use?

A: Symptoms of this infection (CDAD) can range from mild diarrhea to severe colitis. This condition can occur during or even up to two months after antibacterial use. The safety information highlights that severe, persistent diarrhea should be monitored.

---

Q: Is Cefim effective against common community-acquired pneumonia?

A: Official regulatory labeling indicates that Cefixime is approved for a specific list of bacterial infections. Community-acquired pneumonia (CAP) is not listed as an FDA-approved indication on the product label.

---

Q: Is Cefim ever used as a preventative antibiotic?

A: Regulatory warnings state that Cefixime is intended for the treatment of infections proven or strongly suspected to be caused by susceptible bacteria. Prescribing the drug in the absence of a proven infection may increase the risk of developing drug-resistant bacteria.

---

Q: Why is Cefim not used for every type of infection?

A: Cefixime is an antibiotic that is active against a specific range of susceptible bacteria. Official regulatory guidance advises that its use should be reserved for infections proven or strongly suspected to be bacterial in order to manage antibiotic resistance.

---

Q: What research supports the use of Cefim for ear infections?

A: Clinical studies have been conducted for the use of Cefixime in treating Acute Otitis Media (AOM), which is an ear infection. Official labeling notes that for infections caused by certain pathogens like Streptococcus pneumoniae, clinical trial data showed a lower clinical response rate compared to other study drugs.

Official Storage and Disposal Requirements

Storage and disposal instructions for Cefixime are defined by regulatory labeling to ensure product quality and safety. Cefixime solid forms (tablets and capsules) must be stored at Controlled Room Temperature (20 C to 25 C) away from moisture and excess heat. All forms must be protected from freezing and kept in a tightly closed container.

Form	Storage Environment	Stability Constraint
Solid Forms	Controlled Room Temperature	Standard expiry date
Suspension	Room Temperature or Refrigerated	Discard after 14 days of reconstitution

The medicine must be stored out of the reach of children. Unused or expired Cefixime should be disposed of according to the local regulations or by consulting a pharmacist for guidance on proper drug disposal.